title: Attenuation by sphingosine-1-phosphate of rat microvessel acute permeability response to bradykinin is rapidly reversible.
abstract: To evaluate the hypothesis that sphingosine-1-phosphate (S1P) and cAMP attenuate increased permeability of individually perfused mesenteric microvessels through a common Rac1-dependent pathway, we measured the attenuation of the peak hydraulic conductivity (L(p)) in response to the inflammatory agent bradykinin (BK) by either S1P or cAMP. We varied the extent of exposure to each agent (test) and measured the ratio L(p)(test)/L(p)(BK alone) for each vessel (anesthetized rats). S1P (1 μM) added at the same time as BK (concurrent, no pretreatment) was as effective to attenuate the response to BK (L(p) ratio: 0.14 ± 0.05; n = 5) as concurrent plus pretreatment with S1P for 30 min (L(p) ratio: 0.26 ± 0.06; n = 11). The same pretreatment with S1P, but with no concurrent S1P, caused no inhibition of the BK response (L(p) ratio 1.07 ± 0.11; n = 8). The rapid on and off action of S1P demonstrated by these results was in contrast to cAMP-dependent changes induced by rolipram and forskolin (RF), which developed more slowly, lasted longer, and resulted in partial inhibition when given either as pretreatment or concurrent with BK. In cultured endothelium, there was no Rac activation or peripheral cortactin localization at 1 min with RF, but cortactin localization and Rac activation were maximal at 1 min with S1P. When S1P was removed, Rac activation returned to control within 2 min. Because of such differing time courses, S1P and cAMP are unlikely to act through fully common effector mechanisms.
authors.affiliation: Department of Physiology and Membrane Biology, School of Medicine, University of California at Davis, Davis, CA 95616, USA. rhadamson@ucdavis.edu
authors.forename: R H
authors.initials: RH
authors.lastname: Adamson
authors.forename: R K
authors.initials: RK
authors.lastname: Sarai
authors.forename: J F
authors.initials: JF
authors.lastname: Clark
authors.forename: A
authors.initials: A
authors.lastname: Altangerel
authors.forename: T L
authors.initials: TL
authors.lastname: Thirkill
authors.forename: F E
authors.initials: FE
authors.lastname: Curry
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000187:drug effects / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects* / Q000502:physiology; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D008246:Lysophospholipids / Q000494:pharmacology*; D008297:Male; D055806:Microvessels / Q000187:drug effects* / Q000502:physiology; D023421:Models, Animal; D051381:Rats; D020889:Rolipram / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology*; D020830:rac1 GTP-Binding Protein / Q000378:metabolism
chemical_list: D008246:Lysophospholipids; D014665:Vasodilator Agents; D005576:Colforsin; C060506:sphingosine 1-phosphate; D000242:Cyclic AMP; C499134:Rac1 protein, rat; D020830:rac1 GTP-Binding Protein; D020889:Rolipram; D013110:Sphingosine; D001920:Bradykinin